• 2019
  • 2019

    Kari V, Raul SK, Henck JM, Kitz J, Kramer F, Kosinsky RL, Übelmesser N, Mansour WY, Eggert J, Spitzner M, Najafova Z, Bastians H, Grade M, Gaedcke J, Wegwitz F, Johnsen SA. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness. Clin Epigenetics. 2019 Jan 7;11(1):4. doi: 10.1186/s13148-018-0601-1. PubMed PMID: 30616689; PubMed Central PMCID: PMC6323691.

    Dinkelborg PH, Wang M, Gheorghiu L, Gurski JM, Hong TS, Benes CH, Juric D, Jimenez RB, Borgmann K, Willers H. A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types. Breast Cancer Res Treat. 2019 Jan 3. doi: 10.1007/s10549-018-05079-7. [Epub ahead of print] PubMed PMID: 30607635.

    Oing C, Verem I, Mansour WY, Bokemeyer C, Dyshlovoy S, Honecker F. 5-Azacitidine Exerts Prolonged Pro-Apoptotic Effects and Overcomes Cisplatin-Resistance in Non-Seminomatous Germ Cell Tumor Cells. Int J Mol Sci. 2018 Dec 21;20(1). pii: E21. doi: 10.3390/ijms20010021. PubMed PMID: 30577584; PubMed Central PMCID: PMC6337423.

    Seltzsam S, Ziemann F, Dreffke K, Preising S, Arenz A, Schötz U, Engenhart-Cabillic R, Dikomey E, Wittig A. In HPV-Positive HNSCC Cells, Functional Restoration of the p53/p21 Pathway by Proteasome Inhibitor Bortezomib Does Not Affect Radio- or Chemosensitivity. Transl Oncol. 2019 Mar;12(3):417-425. doi: 10.1016/j.tranon.2018.11.013. Epub 2018 Dec 14. PubMed PMID: 30554133; PubMed Central PMCID: PMC6370941.

    Beizaei K, Gleißner L, Hoffer K, Bußmann L, Vu AT, Steinmeister L, Laban S, Möckelmann N, Münscher A, Petersen C, Rothkamm K, Kriegs M. Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC. Head Neck. 2019 Jan;41(1):208-215. doi: 10.1002/hed.25440. Epub 2018 Dec 15. PubMed PMID: 30552828.

    Köcher S, Beyer B, Lange T, Nordquist L, Volquardsen J, Burdak-Rothkamm S, Schlomm T, Petersen C, Rothkamm K, Mansour WY. A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer. Int J Cancer. 2019 Apr 1;144(7):1685-1696. doi: 10.1002/ijc.32018. Epub 2019 Jan 5. PubMed PMID: 30478958.

  • Clauditz TS, Böttcher A, Hanken H, Borgmann K, Sauter G, Wilczak W, Grob T, Münscher A. Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck. J Cancer Res Clin Oncol. 2018 Jan;144(1):53-61. doi: 10.1007/s00432-017-2528-x. Epub 2017 Oct 11. PubMed PMID: 29022097.

    Dogan V, Rieckmann T, Münscher A, Busch CJ. Current studies of immunotherapy in head and neck cancer. Clin Otolaryngol. 2018 Feb;43(1):13-21. doi: 10.1111/coa.12895. Epub 2017 May 29. PubMed PMID: 28464441.

    Mansour WY, Tennstedt P, Volquardsen J, Oing C, Kluth M, Hube-Magg C, Borgmann K, Simon R, Petersen C, Dikomey E, Rothkamm K. Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer. Sci Rep. 2018 Mar 2;8(1):3947. doi: 10.1038/s41598-018-22289-7. PubMed PMID: 29500400; PubMed Central PMCID: PMC5834544.

    Oing C, Tennstedt P, Simon R, Volquardsen J, Borgmann K, Bokemeyer C, Petersen C, Dikomey E, Rothkamm K, Mansour WY. BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy. Cancer Lett. 2018 Jun 1;423:60-70. doi: 10.1016/j.canlet.2018.03.007. Epub 2018 Mar 8. PubMed PMID: 29526801.

    Verhagen CVM, Vossen DM, Borgmann K, Hageman F, Grénman R, Verwijs-Janssen M, Mout L, Kluin RJC, Nieuwland M, Severson TM, Velds A, Kerkhoven R, O'Connor MJ, van der Heijden M, van Velthuysen ML, Verheij M, Wreesmann VB, Wessels LFA, van den Brekel MWM, Vens C. Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects in vitro and poor outcome in patients with advanced head and neck squamous cell carcinoma. Oncotarget. 2018 Apr 6;9(26):18198-18213. doi: 10.18632/oncotarget.24797. eCollection 2018 Apr 6. PubMed PMID: 29719599; PubMed Central PMCID: PMC5915066.

    Gökyildirim MY, Grandel U, Hattar K, Dahlem G, Schuetz E, Leinberger FH, Eberle F, Sibelius U, Grimminger F, Seeger W, Engenhart-Cabillic R, Dikomey E, Subtil FSB. Targeting CREB-binding protein overrides LPS induced radioresistance in non-small cell lung cancer cell lines. Oncotarget. 2018 Jun 22;9(48):28976-28988. doi: 10.18632/oncotarget.25665. eCollection 2018 Jun 22. PubMed PMID: 29989005; PubMed Central PMCID: PMC6034744.

    Schmidt D, Rodat T, Heintze L, Weber J, Horbert R, Girreser U, Raeker T, Bußmann L, Kriegs M, Hartke B, Peifer C. Axitinib: A Photoswitchable Approved Tyrosine Kinase Inhibitor. ChemMedChem. 2018 Nov 20;13(22):2415-2426. doi: 10.1002/cmdc.201800531. Epub 2018 Nov 5. PubMed PMID: 30199151.

    Burdak-Rothkamm S, Rothkamm K. Radiation-induced bystander and systemic effects serve as a unifying model system for genotoxic stress responses. Mutat Res. 2018 Oct - Dec;778:13-22. doi: 10.1016/j.mrrev.2018.08.001. Epub 2018 Aug 17. Review. PubMed PMID: 30454679.

  • Ainsbury EA, Higueras M, Puig P, Einbeck J, Samaga D, Barquinero JF, Barrios L, Brzozowska B, Fattibene P, Gregoire E, Jaworska A, Lloyd D, Oestreicher U, Romm H, Rothkamm K, Roy L, Sommer S, Terzoudi G, Thierens H, Trompier F, Vral A, Woda C. Uncertainty of fast biological radiation dose assessment for emergency response scenarios. Int J Radiat Biol. 2017 Jan;93(1):127-135. doi: 10.1080/09553002.2016.1227106. Epub 2016 Sep 26. PubMed PMID: 27572921.

    Braig F, Kriegs M, Voigtlaender M, Habel B, Grob T, Biskup K, Blanchard V, Sack M, Thalhammer A, Ben Batalla I, Braren I, Laban S, Danielczyk A, Goletz S, Jakubowicz E, Märkl B, Trepel M, Knecht R, Riecken K, Fehse B, Loges S, Bokemeyer C, Binder M. Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K(521) Polymorphism. Cancer Res. 2017 Mar 1;77(5):1188-1199. doi: 10.1158/0008-5472.CAN-16-0754. Epub 2016 Dec 28. PubMed PMID: 28031227.

    Busch CJ, Kröger MS, Jensen J, Kriegs M, Gatzemeier F, Petersen C, Münscher A, Rothkamm K, Rieckmann T. G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1. Radiother Oncol. 2017 Feb;122(2):260-266. doi: 10.1016/j.radonc.2016.11.017. Epub 2016 Dec 9. PubMed PMID: 27939202.

    Eberle F, Leinberger FH, Saulich MF, Seeger W, Engenhart-Cabillic R, Hänze J, Hattar K, Dikomey E, Subtil FSB. In cancer cell lines inhibition of SCF/c-Kit pathway leads to radiosensitization only when SCF is strongly over-expressed. Clin Transl Radiat Oncol. 2017 Feb 28;2:69-75. doi: 10.1016/j.ctro.2017.02.001. eCollection 2017 Feb. PubMed PMID: 29658004; PubMed Central PMCID: PMC5893519.

    Gleißner L, Kwiatkowski M, Myllynen L, Steffen P, Petersen C, Rothkamm K, Schlüter H, Kriegs M. Analyzing the influence of kinase inhibitors on DNA repair by differential proteomics of chromatin-interacting proteins and nuclear phospho-proteins. Oncotarget. 2017 Nov 10;8(67):110983-110993. doi: 10.18632/oncotarget.22424. eCollection 2017 Dec 19. PubMed PMID: 29340031; PubMed Central PMCID: PMC5762299.

    Monteiro Gil O, Vaz P, Romm H, De Angelis C, Antunes AC, Barquinero JF, Beinke C, Bortolin E, Burbidge CI, Cucu A, Della Monaca S, Domene MM, Fattibene P, Gregoire E, Hadjidekova V, Kulka U, Lindholm C, Meschini R, M'Kacher R, Moquet J, Oestreicher U, Palitti F, Pantelias G, Montoro Pastor A, Popescu IA, Quattrini MC, Ricoul M, Rothkamm K, Sabatier L, Sebastià N, Sommer S, Terzoudi G, Testa A, Trompier F, Vral A. Capabilities of the RENEB network for research and large scale radiological and nuclear emergency situations. Int J Radiat Biol. 2017 Jan;93(1):136-141. doi: 10.1080/09553002.2016.1227107. Epub 2016 Oct 4. PubMed PMID: 27557790.

    Moquet J, Barnard S, Staynova A, Lindholm C, Monteiro Gil O, Martins V, Rößler U, Vral A, Vandevoorde C, Wojewódzka M, Rothkamm K. The second gamma-H2AX assay inter-comparison exercise carried out in the framework of the European biodosimetry network (RENEB). Int J Radiat Biol. 2017 Jan;93(1):58-64. doi: 10.1080/09553002.2016.1207822. Epub 2016 Aug 15. PubMed PMID: 27686523.

    Nikolova T, Göder A, Parplys A, Borgmann K. DNA Fiber Spreading Assay to Test HDACi Effects on DNA and Its Replication. Methods Mol Biol. 2017;1510:103-113. PubMed PMID: 27761816.

    Romm H, Ainsbury EA, Barquinero JF, Barrios L, Beinke C, Cucu A, Domene MM, Filippi S, Monteiro Gil O, Gregoire E, Hadjidekova V, Hatzi V, Lindholm C, M Kacher R, Montoro A, Moquet J, Noditi M, Oestreicher U, Palitti F, Pantelias G, Prieto MJ, Popescu I, Rothkamm K, Sebastià N, Sommer S, Terzoudi G, Testa A, Wojcik A. Web based scoring is useful for validation and harmonisation of scoring criteria within RENEB. Int J Radiat Biol. 2017 Jan;93(1):110-117. doi: 10.1080/09553002.2016.1206228. Epub 2016 Aug 22. PubMed PMID: 27547893.

    Wojcik A, Oestreicher U, Barrios L, Vral A, Terzoudi G, Ainsbury E, Rothkamm K, Trompier F, Kulka U. The RENEB operational basis: complement of established biodosimetric assays. Int J Radiat Biol. 2017 Jan;93(1):15-19. doi: 10.1080/09553002.2016.1235296. Epub 2016 Oct 25. PubMed PMID: 27778526.

    Ziemann F, Seltzsam S, Dreffke K, Preising S, Arenz A, Subtil FSB, Rieckmann T, Engenhart-Cabillic R, Dikomey E, Wittig A. Roscovitine strongly enhances the effect of olaparib on radiosensitivity for HPV neg. but not for HPV pos. HNSCC cell lines. Oncotarget. 2017 Oct 24;8(62):105170-105183. doi: 10.18632/oncotarget.22005. eCollection 2017 Dec 1. PubMed PMID: 29285242; PubMed Central PMCID: PMC5739629.

  • Bakr A, Köcher S, Volquardsen J, Petersen C, Borgmann K, Dikomey E, Rothkamm K, Mansour WY. Impaired 53BP1/RIF1 DSB mediated end-protection stimulates CtIP-dependent end resection and switches the repair to PARP1-dependent end joining in G1. Oncotarget 7(36):57679-57693. doi:10.18632/oncotarget.11023.

    Bakr A, Köcher S, Volquardsen J, Reimer R, Borgmann K, Dikomey E, Rothkamm K, Mansour WY. Functional crosstalk between DNA damage response proteins 53BP1 and BRCA1 regulates double strand break repair choice. Radiother Oncol 119(2):276-81. doi: 10.1016/j.radonc.2015.11.001.

    Berte N, Piee-Staffa A, Piecha N, Wang M, Borgmann K, Kaina B, Nikolova T. Targeting homologous recombination by pharmacological inhibitors enhances the killing response of glioblastoma cells treated with alkylating drugs. Mol Cancer Ther 15(11):2665-2678. pii: molcanther.0176.2016.

    Borgmann K, Köcher S, Kriegs M, Mansour WY, Parplys AC, Rieckmann T, Rothkamm K. DNA Repair. Recent Results Cancer Res 198:1-24. doi: 10.1007/978-3-662-49651-0_1.

    Boyd PS, Struve N, Bach M, Eberle JP, Gote M, Schock F, Cremer C, Kriegs M, Hausmann M. Clustered localization of EGFRvIII in glioblastoma cells as detected by high precision localization microscopy. Nanoscale 8(48):20037-20047.

    Braig F, Voigtlaender M, Schieferdecker A, Busch CJ, Laban S, Grob T, Kriegs M, Knecht R, Bokemeyer C, Binder M. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma. Oncotarget 7(28):42988-42995. doi: 10.18632/oncotarget.8943.

    Busch CJ, Becker B, Kriegs M, Gatzemeier F, Krüger K, Möckelmann N, Fritz G, Petersen C, Knecht R, Rothkamm K, Rieckmann T. Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines. Oncotarget 7(24):35832-35842. doi: 10.18632/oncotarget.9028.

    Bussmann L, Busch CJ, Lörincz BB, Rieckmann T, Block A, Knecht R. Perspectives in chemosensitivity and chemoresistance assays and their implementation in head and neck cancer. Eur Arch Otorhinolaryngo 273(12):4073-4080.

    Dickreuter E, Eke I, Krause M, Borgmann K, van Vugt MA, Cordes N. Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells. Oncogene 35(11):1353-62. doi: 10.1038/onc.2015.212.

    Dikomey E, Borgmann K, Kriegs M, Mansour Khalfallah W, Petersen C, Rieckmann T. DNA repair after oncological therapy (radiotherapy and chemotherapy). Oxford Textbook of Oncology. Kerr D, Haller D, van de Velde C, Baumann M (Hrsg.). Third Edition. Aufl. Oxford: Oxford University Press, 82-85.

    Dikomey E, Borgmann K, Köcher S, Kriegs M, Mansour Khalfallah W, Parplys A, Rieckmann T, Rothkamm K. Radiation DNA damage and use in cancer/therapeutics-translation of radiation modifiers. DNA Repair in Cancer Therapy. Kelley M, Fishel M (Hrsg.). London: 329 - 352.

    Eberle F, Saulich MF, Leinberger FH, Seeger W, Engenhart-Cabillic R, Dikomey E, Hänze J, Hattar K, Subtil FS. Cancer cell motility is affected through 3D cell culturing and SCF/c-Kit pathway but not by X-irradiation. Radiother Oncol 119(3):537-43. doi: 10.1016/j.radonc.2016.04.036.

    Foertsch F, Szambowska A, Weise A, Zielinski A, Schlott B, Kraft F, Mrasek K, Borgmann K, Pospiech H, Grosse F, Melle C. S100A11 plays a role in homologous recombination and genome maintenance by influencing the persistence of RAD51 in DNA repair foci. Cell Cycle 15(20):2766-79. doi:10.1080/15384101.2016.1220457.

    Gargioni E, Schulz F, Raabe A, Burdak-Rothkamm S, Rieckmann T, Rothkamm K.Targeted nanoparticles for tumour radiotherapy enhancement-the long dawn of agolden era? Ann Transl Med 4(24):523. doi: 10.21037/atm.2016.12.46.

    Heim D, Gil-Ibanez I, Herden J, Parplys AC, Borgmann K, Schmidt-Arras D, Lohse AW, Rose-John S, Wege H. Constitutive gp130 activation rapidly accelerates the transformation of human hepatocytes via an impaired oxidative stress response. Oncotarget 7(34):55639-55648. doi:10.18632/oncotarget.10956.

    Higueras M, Puig P, Ainsbury EA, Vinnikov VA, Rothkamm K. A new Bayesian model applied to cytogenetic partial body irradiation estimation. Radiat Prot Dosimetry 168(3):330-6. doi: 10.1093/rpd/ncv356.

    Kari V, Mansour WY, Raul SK, Baumgart SJ, Mund A, Grade M, Sirma H, Simon R, Will H, Dobbelstein M, Dikomey E, Johnsen SA. Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. EMBO Rep 17(11):1609-1623. pii: e201642352.

    Köhler C, Koalick D, Fabricius A, Parplys AC, Borgmann K, Pospiech H, Grosse F. Cdc45 is limiting for replication initiation in humans. Cell Cycle 15(7):974-85. doi: 10.1080/15384101.2016.1152424.

    Kriegs M, Kasten-Pisula U, Riepen B, Hoffer K, Struve N, Myllynen L, Braig F, Binder M, Rieckmann T, Grénman R, Petersen C, Dikomey E, Rothkamm K. Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests. Oncotarget 7(29):45122-45133. doi:10.18632/oncotarget.9161.

    Krug D, Baumann R, Rieckmann T, Fokas E, Gauer T, Niyazi M. Situation of young radiation oncologists, medical physicists and radiation biologists in German-speaking countries : Results from a web-based survey of the Young DEGRO working group. Strahlenther Onkol 192(8):507-515.

    Möckelmann N, Kriegs M, Lörincz BB, Busch CJ, Knecht R. Molecular targeting in combination with platinum-based chemoradiotherapy in head and neck cancer treatment. Head Neck 38 Suppl 1:E2173-81. doi: 10.1002/hed.24031.

    Möckelmann N, Rieckmann T, Busch CJ, Becker B, Gleißner L, Hoffer K, Omniczynski M, Steinmeister L, Laban S, Grénman R, Petersen C, Rothkamm K, Dikomey E, Knecht R, Kriegs M. Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells. Oncotarget 7(17):23542-51. doi: 10.18632/oncotarget.8275.

    Nuta O, Somaiah N, Boyle S, Chua ML, Gothard L, Yarnold J, Rothkamm K, Herskind C. Correlation between the radiation responses of fibroblasts cultured from individual patients and the risk of late reaction after breast radiotherapy. Cancer Lett 374(2):324-30. doi: 10.1016/j.canlet.2016.02.036.

    Oliveira M, Einbeck J, Higueras M, Ainsbury E, Puig P, Rothkamm K. Zero-inflated regression models for radiation-induced chromosome aberration data: A comparative study. Biom J. 58(2):259-79. doi: 10.1002/bimj.201400233.

    Pai GM, Zielinski A, Koalick D, Ludwig K, Wang ZQ, Borgmann K, Pospiech H,Rubio I. TSC loss distorts DNA replication programme and sensitises cells togenotoxic stress. Oncotarget 7(51):85365-85380. doi:10.18632/oncotarget.13378.

    Penterling C, Drexler GA, Böhland C, Stamp R, Wilke C, Braselmann H, Caldwell RB, Reindl J, Girst S, Greubel C, Siebenwirth C, Mansour WY, Borgmann K, Dollinger G, Unger K, Friedl AA. Depletion of Histone Demethylase Jarid1A Resulting in Histone Hyperacetylation and Radiation Sensitivity Does Not Affect DNA Double-Strand Break Repair. PLoS One 11(6):e0156599. doi: 10.1371/journal.pone.0156599.

    Riedel M, Struve N, Müller-Goebel J, Köcher S, Petersen C, Dikomey E, Rothkamm K, Kriegs M. Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines. Oncotarget 7(38):61988-61995. doi: 10.18632/oncotarget.11328.

    Salewsky B, Hildebrand G, Rothe S, Parplys AC, Radszewski J, Kieslich M, Wessendorf P, Krenzlin H, Borgmann K, Nussenzweig A, Sperling K, Digweed M. Directed Alternative Splicing in Nijmegen Breakage Syndrome: Proof of Principle Concerning Its Therapeutical Application. Mol Ther 24(1):117-24. doi: 10.1038/mt.2015.144.

    Somaiah N, Chua ML, Bourne S, Daley F, A' Hern R, Nuta O, Gothard L, Boyle S, Herskind C, Pearson A, Warrington J, Helyer S, Owen R, Rothkamm K, Yarnold J. Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy. Radiother Oncol 119(2):244-9. doi: 10.1016/j.radonc.2016.04.012.

    Toulany M, Iida M, Keinath S, Iyi FF, Mueck K, Fehrenbacher B, Mansour WY, Schaller M, Wheeler DL, Peter Rodemann H. Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer. Oncotarget 7(28):43746-43761. doi: 10.18632/oncotarget.9670.

    Trego KS, Groesser T, Davalos AR, Parplys AC, Zhao W, Nelson MR, Hlaing A, Shih B, Rydberg B, Pluth JM, Tsai MS, Hoeijmakers JH, Sung P, Wiese C, Campisi J, Cooper PK. Non-catalytic Roles for XPG with BRCA1 and BRCA2 in Homologous Recombination and Genome Stability. Mol Cell 61(4):535-46. doi: 10.1016/j.molcel.2015.12.026.

    Wurster S, Hennes F, Parplys AC, Seelbach JI, Mansour WY, Zielinski A, Petersen C, Clauditz TS, Münscher A, Friedl AA, Borgmann K. PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response. Oncotarget 7(9):9732-41. doi: 10.18632/oncotarget.6947.

  • Bakr A, Oing C, Köcher S, Borgmann K, Dornreiter I, Petersen C, Dikomey E, Mansour WY. Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation. Nucleic Acids Res. 2015 Mar 31;43(6):3154-66. doi: 10.1093/nar/gkv160. Epub 2015 Mar 9. PubMed PMID: 25753674; PubMed Central PMCID: PMC4381069.

    Barnard S, Ainsbury EA, Al-hafidh J, Hadjidekova V, Hristova R, Lindholm C, Monteiro Gil O, Moquet J, Moreno M, Rößler U, Thierens H, Vandevoorde C, Vral A, Wojewódzka M, Rothkamm K. The first gamma-H2AX biodosimetry intercomparison exercise of the developing European biodosimetry network RENEB. Radiat Prot Dosimetry. 2015 Apr;164(3):265-70. doi: 10.1093/rpd/ncu259. Epub 2014 Aug 12. PubMed PMID: 25118318.

    Bouffler SD, Peters S, Gilvin P, Slack K, Markiewicz E, Quinlan RA, Gillan J, Coster M, Barnard S, Rothkamm K, Ainsbury E. The lens of the eye: exposures in the UK medical sector and mechanistic studies of radiation effects. Ann ICRP. 2015 Jun;44(1 Suppl):84-90. doi: 10.1177/0146645314560693. Epub 2015 Mar 10. PubMed PMID: 25816262.

    Braig F, März M, Schieferdecker A, Schulte A, Voigt M, Stein A, Grob T, Alawi M, Indenbirken D, Kriegs M, Engel E, Vanhoefer U, Grundhoff A, Loges S, Riecken K, Fehse B, Bokemeyer C, Binder M. Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget. 2015 May 20;6(14):12035-47. PubMed PMID: 26059438; PubMed Central PMCID: PMC4494921.

    Burdak-Rothkamm S, Rothkamm K, McClelland K, Al Rashid ST, Prise KM. BRCA1, FANCD2 and Chk1 are potential molecular targets for the modulation of a radiation-induced DNA damage response in bystander cells. Cancer Lett. 2015 Jan 28;356(2 Pt B):454-61. doi: 10.1016/j.canlet.2014.09.043. Epub 2014 Oct 7. PubMed PMID: 25304378; PubMed Central PMCID: PMC4259524.

    Cook R, Zoumpoulidou G, Luczynski MT, Rieger S, Moquet J, Spanswick VJ, Hartley JA, Rothkamm K, Huang PH, Mittnacht S. Direct involvement of retinoblastoma family proteins in DNA repair by non-homologous end-joining. Cell Rep. 2015 Mar 31;10(12):2006-18. doi: 10.1016/j.celrep.2015.02.059. Epub 2015 Mar 26. PubMed PMID: 25818292; PubMed Central PMCID: PMC4386026.

    Higueras M, Puig P, Ainsbury EA, Rothkamm K. A new inverse regression model applied to radiation biodosimetry. Proc Math Phys Eng Sci. 2015 Feb 8;471(2174):20140588. PubMed PMID: 25663804; PubMed Central PMCID: PMC4309124.

    Jaworska A, Ainsbury EA, Fattibene P, Lindholm C, Oestreicher U, Rothkamm K, Romm H, Thierens H, Trompier F, Voisin P, Vral A, Woda C, Wojcik A. Operational guidance for radiation emergency response organisations in Europe for using biodosimetric tools developed in EU MULTIBIODOSE project. Radiat Prot Dosimetry. 2015 Apr;164(1-2):165-9. doi: 10.1093/rpd/ncu294. Epub 2014 Oct 1. Review. PubMed PMID: 25274532.

    Kriegs M, Gurtner K, Can Y, Brammer I, Rieckmann T, Oertel R, Wysocki M, Dorniok F, Gal A, Grob TJ, Laban S, Kasten-Pisula U, Petersen C, Baumann M, Krause M, Dikomey E. Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest. Radiother Oncol. 2015 Apr;115(1):120-7. doi: 10.1016/j.radonc.2015.02.018. Epub 2015 Mar 18. PubMed PMID: 25796091.

    Kulka U, Ainsbury L, Atkinson M, Barnard S, Smith R, Barquinero JF, Barrios L, Bassinet C, Beinke C, Cucu A, Darroudi F, Fattibene P, Bortolin E, Monaca SD, Gil O, Gregoire E, Hadjidekova V, Haghdoost S, Hatzi V, Hempel W, Herranz R, Jaworska A, Lindholm C, Lumniczky K, M'kacher R, Mörtl S, Montoro A, Moquet J, Moreno M, Noditi M, Ogbazghi A, Oestreicher U, Palitti F, Pantelias G, Popescu I, Prieto MJ, Roch-Lefevre S, Roessler U, Romm H, Rothkamm K, Sabatier L, Sebastià N, Sommer S, Terzoudi G, Testa A, Thierens H, Trompier F, Turai I, Vandevoorde C, Vaz P, Voisin P, Vral A, Ugletveit F, Wieser A, Woda C, Wojcik A. Realising the European network of biodosimetry: RENEB-status quo. Radiat Prot Dosimetry. 2015 Apr;164(1-2):42-5. doi: 10.1093/rpd/ncu266. Epub 2014 Sep 9. PubMed PMID: 25205835; PubMed Central PMCID: PMC4401036.

    Markiewicz E, Barnard S, Haines J, Coster M, van Geel O, Wu W, Richards S, Ainsbury E, Rothkamm K, Bouffler S, Quinlan RA. Nonlinear ionizing radiation-induced changes in eye lens cell proliferation, cyclin D1 expression and lens shape. Open Biol. 2015 Apr;5(4):150011. doi: 10.1098/rsob.150011. PubMed PMID: 25924630; PubMed Central PMCID: PMC4422125.

    Moriña D, Higueras M, Puig P, Ainsbury EA, Rothkamm K. radir package: an R implementation for cytogenetic biodosimetry dose estimation. J Radiol Prot. 2015 Sep;35(3):557-69. doi: 10.1088/0952-4746/35/3/557. Epub 2015 Jul 10. PubMed PMID: 26160852.

    Myllynen L, Kwiatkowski M, Gleißner L, Riepen B, Hoffer K, Wurlitzer M, Petersen C, Dikomey E, Rothkamm K, Schlüter H, Kriegs M. Quantitative proteomics unveiled: Regulation of DNA double strand break repair by EGFR involves PARP1. Radiother Oncol. 2015 Sep;116(3):423-30. doi: 10.1016/j.radonc.2015.09.018. Epub 2015 Sep 25. PubMed PMID: 26422459.

    Parplys AC, Seelbach JI, Becker S, Behr M, Wrona A, Jend C, Mansour WY, Joosse SA, Stuerzbecher HW, Pospiech H, Petersen C, Dikomey E, Borgmann K. High levels of RAD51 perturb DNA replication elongation and cause unscheduled origin firing due to impaired CHK1 activation. Cell Cycle. 2015;14(19):3190-202. doi: 10.1080/15384101.2015.1055996. PubMed PMID: 26317153; PubMed Central PMCID: PMC4825602.

    Parplys AC, Zhao W, Sharma N, Groesser T, Liang F, Maranon DG, Leung SG, Grundt K, Dray E, Idate R, Østvold AC, Schild D, Sung P, Wiese C. NUCKS1 is a novel RAD51AP1 paralog important for homologous recombination and genome stability. Nucleic Acids Res. 2015 Nov 16;43(20):9817-34. doi: 10.1093/nar/gkv859. Epub 2015 Aug 31. PubMed PMID: 26323318; PubMed Central PMCID: PMC4787752.

    Reuther S, Szymczak S, Raabe A, Borgmann K, Ziegler A, Petersen C, Dikomey E, Hoeller U. Association between SNPs in defined functional pathways and risk of early or late toxicity as well as individual radiosensitivity. Strahlenther Onkol. 2015 Jan;191(1):59-66. doi: 10.1007/s00066-014-0741-y. Epub 2014 Aug 26. PubMed PMID: 25156511.

    Rothkamm K, Barnard S, Moquet J, Ellender M, Rana Z, Burdak-Rothkamm S. DNA damage foci: Meaning and significance. Environ Mol Mutagen. 2015 Jul;56(6):491-504. doi: 10.1002/em.21944. Epub 2015 Mar 12. Review. PubMed PMID: 25773265.

    Smith RW, Eakins JS, Hager LG, Rothkamm K, Tanner RJ. Development of a retrospective/fortuitous accident dosimetry service based on OSL of mobile phones. Radiat Prot Dosimetry. 2015 Apr;164(1-2):89-92. doi: 10.1093/rpd/ncu370. PubMed PMID: 25841040.

    Somaiah N, Rothkamm K, Yarnold J. Where Do We Look for Markers of Radiotherapy Fraction Size Sensitivity? Clin Oncol (R Coll Radiol). 2015 Oct;27(10):570-8. doi: 10.1016/j.clon.2015.06.006. Epub 2015 Jun 21. PubMed PMID: 26108884.

    Srinivas US, Dyczkowski J, Beißbarth T, Gaedcke J, Mansour WY, Borgmann K, Dobbelstein M. 5-Fluorouracil sensitizes colorectal tumor cells towards double stranded DNA breaks by interfering with homologous recombination repair. Oncotarget. 2015 May 20;6(14):12574-86. PubMed PMID: 25909291; PubMed Central PMCID: PMC4494959.

    Struve N, Riedel M, Schulte A, Rieckmann T, Grob TJ, Gal A, Rothkamm K, Lamszus K, Petersen C, Dikomey E, Kriegs M. EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells. Oncotarget. 2015 Oct 20;6(32):33867-77. doi: 10.18632/oncotarget.5293. PubMed PMID: 26418954; PubMed Central PMCID: PMC4741808.

  • Laban S, Atanackovic D, Luetkens T, Knecht R, Busch CJ, Freytag M, Spagnoli G, Ritter G, Hoffmann TK, Knuth A, Sauter G, Wilczak W, Blessmann M, Borgmann K, Muenscher A, Clauditz TS. Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer.Int J Cancer. 2014; 135:1142-1152

    Kötter A, Cornils K, Borgmann K, Dahm-Daphi J, Petersen C, Dikomey E, Mansour WY. Inhibition of PARP1-dependent end joining contributes to olaparib-mediated radiosensitization in tumor cells. Mol Oncol 2014; 8:1616-1625.

    Reuther S, Szymczak S, Raabe A, Borgmann K, Ziegler A, Petersen C, Dikomey E, Hoeller U. Association between SNPs in defined functional pathways and risk of early or late toxicity as well as individual radiosensitivity. Strahlenther Onkol 2014; 191:59-66.

    Parplys AC, Kratz K, Speed MC, Leung SG, Schild D, Wiese C. RAD51AP1-deficiency in vertebrate cells impairs DNA replication. DNA Repair 2014; 24:87-97.

    Güster JD, Weissleder S, Busch CJ, Kriegs M, Tribius S, Knecht R, Petersen C, Dikomey E, Rieckmann. Inhibition of PARP but not EGFR results in radiosensitzation of HPV and p16-positive HNSCC cell lines. Radiother Oncol 2014; 113:345-351.